Macquarie Group
ALDX icon

Macquarie Group’s Aldeyra Therapeutics ALDX Stock Holding History

Macquarie Group’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-9,791
Closed -$49 – 1710
2024
Q4 		$49 Buy
+9,791
New +$50.2K ﹤0.01% 1641
2018
Q1 		– Sell
-1,400
Closed -$10K – 2158
2017
Q4 		$10K Buy
+1,400
New +$9.22K ﹤0.01% 2259

Other funds holding ALDX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Macquarie Group's ALDX Position: Q1 2025 in Review

Macquarie Group sold out of Aldeyra Therapeutics (ALDX) in Q1 2025, closing a stake of 9,791 shares — an estimated $49 sold.

Macquarie Group first reported a position in ALDX in Q4 2017 and held it in 2 quarters. The position peaked at $10K in Q4 2017. 125 funds tracked by Wall St. Rank hold ALDX as of Q1 2025.

  • Macquarie Group reported no remaining Aldeyra Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Macquarie Group sold 9,791 Aldeyra Therapeutics shares in Q1 2025, an estimated $49.
  • Macquarie Group first reported a position in Aldeyra Therapeutics in Q4 2017 and held it in 2 quarters.
  • Macquarie Group's Aldeyra Therapeutics position peaked at $10K in Q4 2017.
  • 125 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2025.

Based on Macquarie Group's 13F filing for Q1 2025, filed 15 May 2025.